A5055529697- Cystic Fibrosis Research Advances
- Inflammatory Bowel Disease
- Tracheal and airway disorders
- Gut microbiota and health
- Microscopic Colitis
- Barrier Structure and Function Studies
- Genomics and Rare Diseases
- Drug Transport and Resistance Mechanisms
- Immune Cell Function and Interaction
- Mycobacterium research and diagnosis
- Immune Response and Inflammation
- Diet and metabolism studies
- Celiac Disease Research and Management
- Mobile Health and mHealth Applications
- COVID-19 and healthcare impacts
- Gastroesophageal reflux and treatments
- Helicobacter pylori-related gastroenterology studies
- Family and Disability Support Research
- Autoimmune Bullous Skin Diseases
- Diet, Metabolism, and Disease
- FinTech, Crowdfunding, Digital Finance
- Gastrointestinal motility and disorders
- Clostridium difficile and Clostridium perfringens research
- Biochemical Analysis and Sensing Techniques
- Autoimmune and Inflammatory Disorders
Cystic Fibrosis Trust
2021
KU Leuven
2003-2016
Universitair Ziekenhuis Leuven
2000-2001
A primary defect of the tight junctions and, hence, increased intestinal epithelial permeability has been proposed as a basic pathogenic event in Crohn's disease. Challenge mucosal immune system by commensal gut flora would then result chronic inflammation. Alternatively, could be Our aim was to study refractory disease before and after treatment with monoclonal chimeric antibodies directed against tumor necrosis factor (TNF) investigate whether abnormal persists control...
BackgroundSerologic markers anti-Saccharomyces cerevisiae antibodies (ASCA) and antineutrophil cytoplasmic with perinuclear staining (pANCA) have been proposed to study the immunopathogenesis of IBD. Their measurement may allow better phenotyping disease detection subclinical disease.
Aliment Pharmacol Ther 2011; 34: 526–532 Summary Background Butyrate, a colonic metabolite of carbohydrates, is considered as the major energy source for mucosa. An impaired butyrate metabolism has been reported in ulcerative colitis (UC), however, cause still remains unknown. Aim In present study, we investigated whether higher concentrations could normalise oxidation rate UC. Furthermore, it was carnitine enhance oxidation. Methods Mucosal biopsies from total 26 UC patients and 25 controls...
Healthy colonic mucosa uses butyrate as the major energy source. In ulcerative colitis (UC) oxidation has been shown to be disturbed, but it remains unclear whether this is a primary defect. The aim of study was measure mucosal in UC (involved and noninvolved colon) pouchitis relationship with endoscopic well histological disease activity.Butyrate measured 73 patients, 22 112 controls (95 colon, 17 ileum) by incubating biopsies 1 mM 14C-labeled Na-butyrate measuring released 14CO2.Compared...
Crohn's disease (CD) is associated with gut barrier dysfunction. Besides the baseline defect, a subgroup of patients also expresses an intestinal hyperresponsiveness to nonsteroidal anti-inflammatory drugs. We studied whether reducing inflammation and restoring dysfunction anti-tumor necrosis factor (TNF) antibody treatment antagonizes permeability increase by oral drug intake in CD.Thirty-one healthy control subjects 25 active CD were studied. The 31 controls performed testing for Cr-EDTA...
Epithelial barrier disturbance is thought to contribute the pathogenesis of inflammatory bowel diseases; however, it remains unclear whether a primary defect participating onset inflammation or only consequence sustained inflammation.A time course study epithelial functions and immune mediators was performed in CD4(+)CD45RB(hi) T cell transfer model colitis using Ussing chambers.In nonreconstituted severe combined immunodeficiency (SCID) mice, no dysfunction observed. However, after cells...
Abstract This article describes the steps of development and structure a disease-specific clinical trials network for cystic fibrosis in Europe. Activities such as reviewing study protocols, feasibility assessments, training standardizing procedures, outcome measurements help to bring high-quality patients. Cooperation with pharmaceutical industry, other research networks, patient organizations, regulatory agencies is very important throughout all activities. Conclusion : The European Cystic...
Background: Smoking reduces the non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal permeability increase in healthy people. It also affects inflammatory bowel disease that is associated with a disturbed gut barrier function. To assess role of nicotine on function, its influence basal and NSAID-induced was studied volunteers. Methods: Thirty-one non-smoker subjects performed tests 51Cr-EDTA sugar markers (sucrose, lactulose, mannitol, sucralose) before during 2 weeks patch...
The European Cystic Fibrosis Society–Clinical Trials Network was established in 2009 as an initiative of the learned Society. Its aim is to optimize development and evaluation new approved treatments for cystic fibrosis through efficient clinical studies Europe. composed 30 selected sites across 11 countries. activities are supported by a coordinating center, steering executive committees protocol review, standardization, training, networking data safety monitoring board. current projects...
Clinical trial networks provide a centralized resource for the successful execution of clinical trial. For diseases with relatively small populations, such as cystic fibrosis, most appropriate action is to form larger operational group. The rationale setting up European Trials Network fibrosis bring new medications patients faster. A protocol review will improve quality and feasibility studies. Standardization outcome parameters help decrease variation results therefore sample size needed....
<b>Introduction:</b> ECFS-CTN started operations in 2009 to intensify clinical research and overcome the challenges of trials cystic fibrosis (CF), with aim bringing new therapies patients as quickly possible. represents 58 sites 17 countries, caring for 21,500 patients. <b>Activities:</b> prioritise which protocol has been reviewed approved by teams CF doctors, coordinators, statisticians patient/parents. This improves trial design, ensures an acceptable burden participation prioritises...
Abstract The SARS-CoV-2 pandemic has disrupted clinical trials worldwide. European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) tracked trial disruption by surveying its 58 sites across 17 countries and collated information on measures to mitigate the impact of ensure continuity. Here we present recommendations how reduce risk exposure patients staff implementing remote visits where possible, using home assessments, video phone calls, electronic consent delivery study drug. We...